BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Chen R, Gao Z, Wu X, Campbell JL, Zhang P, Chen B. Hepatocellular carcinoma presenting as thoracic spinal canal metastasis with no clinical primary foci: A report of a rare case and review of the literature. Oncol Lett 2015;10:2333-6. [PMID: 26622846 DOI: 10.3892/ol.2015.3569] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
2 Nathan H, Herlong HF, Gurakar A, Li Z, Koteish AA, Bridges JF, Pawlik TM. Clinical Decision-Making by Gastroenterologists and Hepatologists for Patients with Early Hepatocellular Carcinoma. Ann Surg Oncol 2014;21:1844-51. [DOI: 10.1245/s10434-014-3536-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Kim NH, Lee T, Cho YK, Kim BI, Kim HJ. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization: Clinically evident portal hypertension. Journal of Gastroenterology and Hepatology 2018;33:1397-406. [DOI: 10.1111/jgh.14083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
4 Santambrogio R, Opocher E, Costa M, Barabino M, Zuin M, Bertolini E, De Filippi F, Bruno S. Hepatic resection for “BCLC stage A” hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. Ann Surg Oncol. 2012;19:426-434. [PMID: 21732145 DOI: 10.1245/s10434-011-1845-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
5 Xing M, Sakaria S, Dhanasekaran R, Parekh S, Spivey J, Knechtle SJ, Zhang D, Kim HS. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2017;40:410-420. [PMID: 27900445 DOI: 10.1007/s00270-016-1505-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhao WC, Zhang HB, Yang N, Fu Y, Qian W, Chen BD, Fan LF, Yang GS. Preoperative predictors of short-term survival after hepatectomy for multinodular hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3272-3281 [PMID: 22783052 DOI: 10.3748/wjg.v18.i25.3272] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
7 Hong YJ, Kim SH, Choi GH, Kim KS, Choi JS. Long-term outcome after liver resection and clinicopathological features in patients with small hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg 2011;15:199-205. [PMID: 26421040 DOI: 10.14701/kjhbps.2011.15.4.199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
8 Ali JM, Bonomo L, Brais R, Griffiths WJ, Lomas DJ, Huguet EL, Praseedom RK, Jamieson NV, Jah A. Outcomes and Diagnostic Challenges Posed by Incidental Cholangiocarcinoma After Liver Transplantation. Transplantation 2011;91:1392-7. [DOI: 10.1097/tp.0b013e31821aba57] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
9 Pawlik TM. Emerging therapeutic approaches to hepatocellular carcinoma. Ann Surg Oncol 2010;17:1217-8. [PMID: 20405325 DOI: 10.1245/s10434-010-1012-5] [Reference Citation Analysis]
10 Qiu J, Zheng Y, Shen J, Zeng Q, Zou R, Liao Y, He W, Li Q, Chen G, Li B, Yuan Y. Resection versus ablation in hepatitis B virus−related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study. Surgery 2015;158:1235-43. [DOI: 10.1016/j.surg.2015.04.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
11 Santambrogio R, Costa M, Barabino M, Zuin M, Bertolini E, De Filippi F, Bruno S, Opocher E. Recurrent hepatocellular carcinoma successfully treated with laparoscopic thermal ablation. Surg Endosc 2012;26:1108-15. [PMID: 22044972 DOI: 10.1007/s00464-011-2007-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zhao WC, Yang N, Zhu N, Zhang HB, Fu Y, Zhou HB, Cai WK, Chen BD, Yang GS. Patients with multiple hepatocellular carcinomas within the UCSF criteria have outcomes after curative resection similar to patients within the BCLC early-stage criteria. World J Surg. 2012;36:1811-1823. [PMID: 22526045 DOI: 10.1007/s00268-012-1601-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
13 Nathan H, Bridges JF, Schulick RD, Cameron AM, Hirose K, Edil BH, Wolfgang CL, Segev DL, Choti MA, Pawlik TM. Understanding surgical decision making in early hepatocellular carcinoma. J Clin Oncol 2011;29:619-25. [PMID: 21205759 DOI: 10.1200/JCO.2010.30.8650] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
14 Huang SF, Wu HD, Chen YT, Murthy SR, Chiu YT, Chang Y, Chang IC, Yang X, Loh YP. Carboxypeptidase E is a prediction marker for tumor recurrence in early-stage hepatocellular carcinoma. Tumour Biol 2016;37:9745-53. [PMID: 26803519 DOI: 10.1007/s13277-016-4814-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
15 Li Y, Ruan D, Yi H, Wang G, Yang Y, Jiang N. A three-factor preoperative scoring model predicts risk of recurrence after liver resection or transplantation in hepatocellular carcinoma patients with preserved liver function. Hepatobiliary & Pancreatic Diseases International 2015;14:477-84. [DOI: 10.1016/s1499-3872(15)60412-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
16 Muscari F, Foppa B, Carrere N, Kamar N, Peron J, Suc B. Resection of a Transplantable Single-Nodule Hepatocellular Carcinoma in Child-Pugh Class A Cirrhosis: Factors Affecting Survival and Recurrence. World J Surg 2011;35:1055-62. [DOI: 10.1007/s00268-011-1000-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
17 Li W, Wang Y, Kellner DB, Zhao L, Xu L, Gao Q. Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma. Oncol Lett. 2016;12:707-714. [PMID: 27347204 DOI: 10.3892/ol.2016.4629] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
18 Peng W, Li C, Zhu W, Wen T, Yan L, Li B, Wang W, Yang J. Prognostic value of the platelet to lymphocyte ratio change in liver cancer. Journal of Surgical Research 2015;194:464-70. [DOI: 10.1016/j.jss.2014.12.021] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
19 Hu Z, Zhang Q, Zhou J, Li Z, Xiang J, Zhou L, Wu J, Zhang M, Zheng S. Impact of multiple liver resections prior to salvage liver transplantation on survival in patients with recurrent HCC. BMJ Open 2015;5:e008429. [PMID: 26353871 DOI: 10.1136/bmjopen-2015-008429] [Reference Citation Analysis]
20 Qi X, Zhang X, Li Z, Hui J, Xiang Y, Chen J, Zhao J, Li J, Qi FZ, Xu Y. HVPG signature: A prognostic and predictive tool in hepatocellular carcinoma. Oncotarget 2016;7:62789-96. [PMID: 27566593 DOI: 10.18632/oncotarget.11558] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
21 Nathan H, Segev DL, Bridges JFP, Massie AB, Cameron AM, Hirose K, Schulick RD, Choti MA, Pawlik TM. Influence of Nonclinical Factors on Choice of Therapy for Early Hepatocellular Carcinoma. Ann Surg Oncol 2013;20:448-56. [DOI: 10.1245/s10434-012-2619-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
22 Zhang K, Chen R, Gong X, Gao Y. Survival outcomes of liver transplantation versus liver resection among patients with hepatocellular carcinoma: A SEER-based longitudinal study. Journal of the Formosan Medical Association 2019;118:790-6. [DOI: 10.1016/j.jfma.2018.09.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Liu PH, Lee YH, Hsu CY, Huang YH, Chiou YY, Lin HC, Huo TI. Survival advantage of radiofrequency ablation over transarterial chemoembolization for patients with hepatocellular carcinoma and good performance status within the Milan criteria. Ann Surg Oncol. 2014;21:3835-3843. [PMID: 24903236 DOI: 10.1245/s10434-014-3831-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
24 Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, Lee FY, Huo TI. Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the milan criteria. Ann Surg Oncol 2013;20:2035-42. [PMID: 23306955 DOI: 10.1245/s10434-012-2847-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
25 Hou YF, Wei YG, Yang JY, Wen TF, Xu MQ, Yan LN, Li B. Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC. Hepatobiliary Pancreat Dis Int. 2016;15:378-385. [PMID: 27498577 DOI: 10.1016/s1499-3872(16)60089-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
26 Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang N, An X, Yu J, Li H, Ren X. A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma. J Clin Immunol. 2014;34:194-203. [PMID: 24337625 DOI: 10.1007/s10875-013-9976-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
27 Li C, Zhu W, Wen T, Dai Y, Yan L, Li B, Yang J, Wang W, Xu M. Child-Pugh A Hepatitis B-Related Cirrhotic Patients with a Single Hepatocellular Carcinoma Up to 5 cm: Liver Transplantation vs. Resection. J Gastrointest Surg 2014;18:1469-76. [DOI: 10.1007/s11605-014-2550-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
28 Squires MH, Hanish SI, Fisher SB, Garrett C, Kooby DA, Sarmiento JM, Cardona K, Adams AB, Russell MC, Magliocca JF. Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. J Surg Oncol. 2014;109:533-541. [PMID: 24347475 DOI: 10.1002/jso.23531] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
29 Sun X, Li RU, Zhang B, Yang Y, Cui Z. Treatment of liver cancer of middle and advanced stages using ultrasound-guided percutaneous ethanol injection combined with radiofrequency ablation: A clinical analysis. Oncol Lett 2016;11:2096-100. [PMID: 26998128 DOI: 10.3892/ol.2016.4180] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Rauchfuss F, Scheuerlein H, Götz M, Dittmar Y, Voigt R, Heise M, Settmacher U. [Hepatocellular carcinoma and cholangiocarcinoma]. Chirurg 2010;81:941-52; quiz 953. [PMID: 20827454 DOI: 10.1007/s00104-009-1864-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
31 Yang G, Dong K, Zhang Z, Zhang E, Liang B, Chen X, Huang Z. EXO1 Plays a Carcinogenic Role in Hepatocellular Carcinoma and is related to the regulation of FOXP3. J Cancer 2020;11:4917-32. [PMID: 32626539 DOI: 10.7150/jca.40673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Lin SY, Chen CM, Huang BS, Lai YC, Pan KT, Lin SM, Chu SY, Tseng JH. A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness. PLoS One 2021;16:e0249003. [PMID: 33755701 DOI: 10.1371/journal.pone.0249003] [Reference Citation Analysis]
33 Wong TCL, Cheung TT, Chok KSH, Chan ACY, Dai WC, Chan SC, Poon RTP, Lo CM. Treatment Strategy to Improve Long-Term Survival for Hepatocellular Carcinoma Smaller than 5 cm: Major Hepatectomy vs Minor Hepatectomy. World J Surg 2014;38:2386-94. [DOI: 10.1007/s00268-014-2601-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
34 Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther. 2014;14:1205-1218. [PMID: 25199765 DOI: 10.1586/14737140.2014.949246] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
35 Qi WX, Fu S, Zhang Q, Guo XM. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol. 2015;114:289-295. [PMID: 25497556 DOI: 10.1016/j.radonc.2014.11.033] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 7.9] [Reference Citation Analysis]
36 Dionisi F, Widesott L, Lorentini S, Amichetti M. Is there a role for proton therapy in the treatment of hepatocellular carcinoma? A systematic review. Radiotherapy and Oncology 2014;111:1-10. [DOI: 10.1016/j.radonc.2014.02.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
37 Cucchetti A, Cescon M, Trevisani F, Pinna AD. Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. World J Gastroenterol 2012; 18(44): 6398-6408 [PMID: 23197885 DOI: 10.3748/wjg.v18.i44.6398] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
38 Qiu JL, Huang PZ, You JH, Zou RH, Wang L, Hong J, Li BK, Zhou K, Yuan YF. Lin28 expression and prognostic value in hepatocellular carcinoma patients who meet the Milan criteria and undergo hepatectomy. Chin J Cancer. 2012;31:223-232. [PMID: 22429493 DOI: 10.5732/cjc.011.10426] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
39 Shi J, Keller JM, Zhang J, Keller ET. A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors. J Hepatocell Carcinoma 2014;1:1-7. [PMID: 27508171 DOI: 10.2147/JHC.S44537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
40 Hu GY, Huang ZS. Study progress in immune escape mechanism and immunotherapy for primary hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(15): 2116-2121 [DOI: 10.11569/wcjd.v22.i15.2116] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Dhir M, Lyden ER, Smith LM, Are C. Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. HPB (Oxford). 2012;14:635-645. [PMID: 22882201 DOI: 10.1111/j.1477-2574.2012.00500.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 6.0] [Reference Citation Analysis]
42 Lee YH, Hsia CY, Hsu CY, Huang YH, Lin HC, Huo TI. Total tumor volume is a better marker of tumor burden in hepatocellular carcinoma defined by the Milan criteria. World J Surg 2013;37:1348-55. [PMID: 23467925 DOI: 10.1007/s00268-013-1978-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
43 Ke M, Zhang Z, Xu B, Zhao S, Ding Y, Wu X, Wu R, Lv Y, Dong J. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. Int Immunopharmacol 2019;75:105824. [PMID: 31437792 DOI: 10.1016/j.intimp.2019.105824] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
44 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 173] [Article Influence: 21.1] [Reference Citation Analysis]
45 Xu B, Li KP, Shen F, Xiao HQ, Cai WS, Li JL, Liu QC, Jia L. Ulinastatin reduces cancer recurrence after resection of hepatic metastases from colon cancer by inhibiting MMP-9 activation via the antifibrinolytic pathway. Biomed Res Int 2013;2013:437950. [PMID: 23710449 DOI: 10.1155/2013/437950] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
46 Brunello F, Cantamessa A, Gaia S, Carucci P, Rolle E, Castiglione A, Ciccone G, Rizzetto M. Radiofrequency ablation: technical and clinical long-term outcomes for single hepatocellular carcinoma up to 30 mm. Eur J Gastroenterol Hepatol. 2013;25:842-849. [PMID: 23442417 DOI: 10.1097/meg.0b013e32835ee5f1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
47 Huo L, Dang Y, Lv J, Xing H, Li F. Application of dual phase imaging of 11C-acetate positron emission tomography on differential diagnosis of small hepatic lesions. PLoS One. 2014;9:e96517. [PMID: 24816814 DOI: 10.1371/journal.pone.0096517] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
48 Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Pai JT, Loong CC, Chiou YY, Lee RC, Lee FY, Huo TI, Lee SD. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol. 2012;19:842-849. [PMID: 21913008 DOI: 10.1245/s10434-011-2060-1] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 7.8] [Reference Citation Analysis]
49 Youness RA, Rahmoon MA, Assal RA, Gomaa AI, Hamza MT, Waked I, El Tayebi HM, Abdelaziz AI. Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression. Growth Factors 2016;34:128-40. [PMID: 27388576 DOI: 10.1080/08977194.2016.1200571] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
50 Hou YF, Li B, Wei YG, Yang JY, Wen TF, Xu MQ, Yan LV, Chen KF. Second Hepatectomy Improves Survival in Patients With Microvascular Invasive Hepatocellular Carcinoma Meeting the Milan Criteria. Medicine (Baltimore) 2015;94:e2070. [PMID: 26632890 DOI: 10.1097/MD.0000000000002070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
51 Barreto SG, Brooke-Smith M, Dolan P, Wilson TG, Padbury RT, Chen JW. Cirrhosis and microvascular invasion predict outcomes in hepatocellular carcinoma. ANZ J Surg. 2013;83:331-335. [PMID: 22943449 DOI: 10.1111/j.1445-2197.2012.06196.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
52 Sawada T, Kubota K, Kita J, Kato M, Shiraki T, Park K, Shimoda M. Clinical outcome of hepatectomy for hepatocellular carcinomas≤2 cm. World J Surg 2011;35:377-85. [PMID: 21042908 DOI: 10.1007/s00268-010-0851-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
53 Zhu Y, Dong J, Wang WL, Li MX, Lu Y. Short- and long-term outcomes after salvage liver transplantation versus primary liver transplantation for hepatocellular carcinoma: a meta-analysis. Transplant Proc 2013;45:3329-42. [PMID: 24182812 DOI: 10.1016/j.transproceed.2013.06.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
54 Madkhali AA, Fadel ZT, Aljiffry MM, Hassanain MM. Surgical treatment for hepatocellular carcinoma. Saudi J Gastroenterol. 2015;21:11-17. [PMID: 25672233 DOI: 10.4103/1319-3767.151216] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
55 Hou YF, Wei YG, Yang JY, Wen TF, Xu MQ, Yan LN, Li B, Chen KF. Microvascular invasion patterns affect survival in hepatocellular carcinoma patients after second hepatectomy. J Surg Res 2016;200:82-90. [PMID: 26259778 DOI: 10.1016/j.jss.2015.06.069] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
56 Harada N, Shirabe K, Maeda T, Kayashima H, Takaki S, Maehara Y. Comparison of the Outcomes of Patients with Hepatocellular Carcinoma and Portal Hypertension After Liver Resection Versus Radiofrequency Ablation. World J Surg 2016;40:1709-19. [DOI: 10.1007/s00268-016-3465-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
57 Shi HY, Lee KT, Lee HH, Ho WH, Sun DP, Wang JJ, Chiu CC. Comparison of artificial neural network and logistic regression models for predicting in-hospital mortality after primary liver cancer surgery. PLoS One. 2012;7:e35781. [PMID: 22563399 DOI: 10.1371/journal.pone.0035781] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
58 Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96:e5904. [PMID: 28248853 DOI: 10.1097/md.0000000000005904] [Cited by in Crossref: 74] [Cited by in F6Publishing: 49] [Article Influence: 14.8] [Reference Citation Analysis]
59 Xu H, Deng Y, Zhou Z, Huang Y. Chinese Herbal Medicine (Chaihu-Huaji Decoction) Alleviates Postembolization Syndrome following Transcatheter Arterial Chemoembolization and Improves Survival in Unresectable Hepatocellular Cancer: A Retrospective Study. Evid Based Complement Alternat Med 2019;2019:6269518. [PMID: 30854013 DOI: 10.1155/2019/6269518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]